

# Colorectal Cancer Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Therapies

## *Colorectal Cancer Pipeline*

DELHI, DELHI, INDIA, July 1, 2024

/EINPresswire.com/ -- DelveInsight's, "Colorectal Cancer Pipeline Insight 2024" report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.



colorectal cancer pipeline

## Key Takeaways from the Colorectal Cancer Pipeline Report

- DelveInsight's Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Colorectal Cancer treatment.
- The leading Colorectal Cancer Companies working in the market include Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
- Promising Colorectal Cancer Therapies in the various stages of development include Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEP11018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitoxin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAD703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-

8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.

- May 2024:- Novartis Pharmaceuticals- An Open-label, Multi-center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors. The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with tislelizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to treat those cancers.
- May 2024:- Seagen Inc.- An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer. This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.

Request a sample and discover the recent advances in Colorectal Cancer @ [Colorectal Cancer Pipeline Outlook](#)

### Colorectal Cancer Overview

Colorectal cancer (CRC) is a disorder that occurs exclusively in the colon or rectum and is caused by the colon's aberrant proliferation of glandular epithelial cells. There are three principal types of CRC: sporadic, hereditary, and colitis-associated. The number of CRC cases is increasing globally day by day. Both environmental and genetic factors determine the risk of developing CRC. In addition, the risk of developing CRC in patients with long-standing ulcerative colitis and Crohn's disease increases with age. Multiple studies have demonstrated that risk factors for CRC include diet and lifestyle, family history, and chronic inflammation.

### Colorectal Cancer Emerging Drugs Profile

- XL092 : Exelixis
- Adagrasb : Mirati Therapeutics
- Olaparib : Merck Sharp & Dohme LLC/Astrazeneca
- DS-8201: Daiichi Sankyo
- Ompenaclid: Inspirna
- LYL845: Lyell Immunopharma
- RG6286: Genentech

Learn more about the Colorectal Cancer ongoing clinical trials @ [Colorectal Cancer Drugs](#)

### Colorectal Cancer Therapeutics Assessment

There are approx. 195+ key Colorectal Cancer companies which are developing the Colorectal

Cancer therapies. The Colorectal Cancer Companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Exelixis.

DelveInsight's Colorectal Cancer pipeline report covers around 200+ products under different phases of clinical development like

- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Discover more about Colorectal Cancer in development @ [Colorectal Cancer Clinical Trials](#)

### Colorectal Cancer Companies

Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical

Colorectal Cancer Products have been categorized under various Molecule types such as

- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy

To know more about Colorectal Cancer, visit @ Colorectal Cancer Segmentation-  
[https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=promotion&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=einpresswire&utm_medium=promotion&utm_campaign=ypr)

### Scope of the Colorectal Cancer Pipeline Report

- Coverage- Global
- Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination,

## Mono/Combination

- Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
- Colorectal Cancer Therapies- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEP11018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.

For further information on the Colorectal Cancer pipeline therapeutics, reach out @ Colorectal Cancer Products Development- [https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=promotion&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=einpresswire&utm_medium=promotion&utm_campaign=ypr)

## Table of Content

1. Introduction
2. Executive Summary
3. Colorectal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. XL092: Exelixis
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Early Stage Products (Phase I)
12. LYL845: Lyell Immunopharma
13. Inactive Products
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Colorectal Cancer - Unmet Needs
17. Colorectal Cancer - Market Drivers and Barriers
18. Colorectal Cancer - Future Perspectives and Conclusion
19. Colorectal Cancer Analyst Views

20. Colorectal Cancer Key Companies

21. Appendix

#### About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj

DelveInsight

+91 9650213330

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/724280774>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.